New drug CPO107 tested in lymphoma patients – early trial stopped
NCT ID NCT04853329
First seen Apr 10, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This early study tested a new drug, CPO107, in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD20 POSITIVE NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novant Health
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.